Fintel on MSN

Morgan Stanley downgrades Regeneron Pharmaceuticals (REGN)

Fintel reports that on December 3, 2025, Morgan Stanley downgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN ...
Nasdaq

Cantor Fitzgerald Maintains Regeneron Pharmaceuticals (REGN) Overweight Recommendation

Fintel reports that on October 29, 2025, Cantor Fitzgerald maintained coverage of Regeneron Pharmaceuticals (NasdaqGS:REGN) with a Overweight recommendation. As of October 29, 2025, the average ...
Business Insider

Regeneron Highlights Progress at American Society of Hematology (ASH), with Updated Data in Multiple Myeloma, Lymphoma and Paroxysmal Nocturnal Hemoglobinuria Programs

Oral presentation of Lynozyfic™ (linvoseltamab-gcpt) data in newly diagnosed multiple myeloma from LINKER-MM4, the first trial to evaluate a BCMAxCD3 bispecific antibody as a monotherapy in this ...
Seeking Alpha

Market Starting To Embrace The 'New' Regeneron

Regeneron Pharmaceuticals, Inc. beat Q3 revenue and EPS expectations, and it appears investors are finally embracing the fact that the Eylea franchise is no longer a growth product. Eylea franchise ...